234 results about "Renal filtrate" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The invention relates to the technical field of medical data analysis, in particular to a kidney injury prediction system based on big data, which comprises a physiological data processing module, a fluctuation analysis construction module, a dynamic weight evaluation module, a cross-domain data scheduling module and a risk trend prediction module. According to the method, through timestamp standardization and continuous recombination of the acute kidney injury physiological data, the consistency of multi-source monitoring data in the time dimension is ensured, drifting and dislocation are eliminated, the time sequence integrity is improved, fluctuation points of serum creatinine and urine volume are extracted, sensitive time slices are recognized, and high-risk time point early warning is achieved; a rate change comparison mechanism is introduced, a physiological factor weight sequence is generated, factor influence evaluation is enhanced, uploading frequency and a time delay state are combined, high-reliability nodes are screened, data continuity and real-time performance are improved, index trend deviation is tracked, a mode label is generated, and timeliness and accuracy of renal function change prediction are improved.

The invention provides a method and a system for predicting an Alport syndrome through a multi-modal retina image based on deep learning, and relates to the technical field of deep learning. According to the method, a retina image, an OCT image and clinical text data are fused, a dual-channel deep neural network of an image encoder and a text encoder is constructed, semantic alignment pre-training is carried out by adopting multi-modal contrast learning, and an adversarial sample enhancement mechanism is introduced to improve model robustness; unified standardized training of different device images is achieved through the style migration module, the occurrence probability and the renal function progress risk level are finally output, and high-reliability prediction under the cross-modal and cross-device condition is achieved.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The invention relates to the technical field of medical treatment, in particular to an intelligent general surgery preoperative risk assessment system which comprises a data acquisition module, a data fusion and processing module, a feature extraction module, a risk assessment module, a prediction and optimization module and a visual display module. The data fusion and processing module adopts a multi-modal data fusion algorithm to generate a patient comprehensive information model, the feature extraction module extracts cardiovascular health status, renal function and tumor marker key features, and the risk assessment module constructs a preoperative risk assessment model to generate a preoperative risk score; the prediction and optimization module predicts the risk of postoperative complications, and the visual display module displays an evaluation result and a prediction result in real time through a graphical interface; according to the method, the accuracy and scientificity of preoperative risk assessment and postoperative complication prediction are remarkably improved, and reliable support is provided for postoperative management of patients.

The invention relates to the technical field of data processing, and discloses an old-age multi-organ function decline rehabilitation prediction method and system based on artificial intelligence. The method comprises the following steps: screening cardiovascular, respiratory, renal function and liver function indexes of an elderly patient through a multi-source data quality evaluation matrix, carrying out time sequence synchronization according to visceral organ physiology time delay characteristics, adopting a visceral organ function correlation positioning analysis algorithm to identify a collaborative decline mode and calculating 1-NN similarity and Max-NN correlation decline degree, and finally, inputting target patient data into a special prediction model of a corresponding hierarchical group to generate a rehabilitation prediction result. According to the method and the device, the technical problem that an existing senile multi-organ function decline prediction method lacks parameter-free collaborative decline mode recognition and individualized layered prediction is solved.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 16 to 24 parts of astragalus membranaceus, 24 to 36 parts of poria cocos, 24 to 36 parts of motherwort herb, 16 to 24 parts of herba pyrolae, 24 to 36 parts of hairyvein agrimony, 24 to 36 parts of herba ardisiae japonicae, 16 to 24 parts of dianthus superbus, 16 to 24 parts of cluster mallow fruit and 6.4 to 9.6 parts of tetrapanax papyriferus. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention can safely and effectively improve the renal function of patients suffering from chronic kidney diseases such as qi deficiency, blood stasis and damp turbidity accumulation, relieve clinical symptoms and delay disease progression, and a traditional Chinese medicine scheme with an exact curative effect is provided for clinically treating the diseases.

The invention provides a traditional Chinese medicine composition for treating urolithiasis. Specifically, the invention provides a traditional Chinese medicine composition consisting of glechoma longituba, semen plantaginis, pyrrosia lingua, radix achyranthis bidentatae, radix paeoniae alba, radix puerariae and honey-fried licorice root. The traditional Chinese medicine composition is simple in formula and exact in clinical curative effect. The composition is used for treating urolithiasis, can effectively relieve kidney crystallization and renal tubule injury and improve the renal function, and has the application prospect in the field of urolithiasis treatment.

The invention discloses a traditional Chinese medicine and probiotic composition and application thereof, and belongs to the technical field of medicines. The composition is prepared from a traditional Chinese medicine extract and lactobacillus brevis DMU22441 (the preservation number is CGMCC No.65301), wherein the traditional Chinese medicine extract is prepared from fructus gardeniae, rhizoma phragmitis and flos sophorae according to the mass ratio of 1: 1: 1. The traditional Chinese medicine extract is prepared through an ethanol extraction method, and the viable count of probiotics is 10 < 9 > CFU / day. According to the composition, through a three-in-one synergistic mechanism of inhibiting synthesis, promoting excretion and regulating flora, the serum uric acid level is remarkably reduced, renal function impairment is improved, and intestinal flora imbalance is regulated. The invention provides an efficient and safe multi-target solution for the treatment of hyperuricemia and complications thereof, and has significant clinical application value.

The invention discloses an AKI, CKD and AKI-CKD progress general prediction model based on plasma proteomics and a construction method thereof. The construction method comprises the following steps: selecting a patient which has plasma proteomics data when a baseline which meets the inclusion standard of a research group, has eGFR greater than or equal to 60mL / min / 1.73 m < 2 > when the baseline exists, and has no AKI or CKD medical history; collecting clinical prediction factors and blood proteomics data of the modeling crowd; and randomly dividing the selected modeling crowd data into a training set and a verification set, screening out protein prediction markers such as protein WFDC2 and protein GDF15 shared with the development of the AKI, the CKD and the AKI-CKD, and establishing a general prediction model for the development of the AKI, the CKD and the AKI-CKD. Proteomics is used for predicting AKI-CKD progress for the first time, three renal function outcomes can be predicted at the same time, prediction indexes are simple and easy to obtain, and the model is a universal model with high prediction capacity.

Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and / or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.

This utility model relates to the field of urine collection bag technology and discloses a urine collection bag for bladder irrigation in urological patients. It includes a lifting arm and a urine collection bag. A hook is fixedly connected to the middle of the upper surface of the lifting arm, and a warning light is installed in the middle of one side of the lifting arm. A power supply is installed inside the lifting arm. Slides are formed on both sides of the lifting arm. A conductive block is fixedly connected to one side of the bottom wall of the slide, and a spring is fixedly connected to the other side of the bottom wall of the slide. An inlet pipe is fixedly connected to one side of the upper surface of the urine collection bag, and a drain pipe is fixedly connected to the middle of the lower surface of the urine collection bag. This urine collection bag for bladder irrigation, through the design of an observation window and built-in scale lines, reduces the interference of bag deformation and light refraction on readings. Nursing staff can intuitively and accurately read the volume of irrigation waste fluid, ensuring accurate recording of intake and output balance, and providing reliable data support for assessing the patient's bladder irrigation effect, bleeding, and renal function recovery.

The invention belongs to the technical field of kidney disease detection, and particularly relates to a renal function dry-type biochemical detection chip and a use method thereof. The chip is combined with a dry biochemical reaction layer through a micro-fluidic technology, and can be used for synchronously detecting renal function markers such as urine creatinine, urea nitrogen and cystatin C. The chip adopts a multi-layer modular lamination design, and sequentially comprises a bottom plate, an electrode layer, a detection layer, a binding layer and a sample adding layer from bottom to top, and each layer is made of a high-molecular polymer with excellent biocompatibility, so that the detection process is not interfered, and the result is accurate and reliable. Sample flow is accurately controlled through the microfluidic channel, multi-index parallel detection is realized, and the detection efficiency is improved. A micro sensor is arranged in the chip, the reaction process is monitored in real time, and data accuracy is ensured. The system has the characteristics of portability and quick response, is suitable for clinical and family self-test, and provides a convenient and efficient solution for renal function monitoring.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

The invention discloses a construction method of a pulmonary arterial hypertension traditional Chinese medicine syndrome model, and aims to simulate a pulmonary arterial hypertension animal model with syndrome characteristics of heart-kidney yang deficiency. The method comprises the following steps: inducing rat pulmonary arterial hypertension pathological basis by adopting monocrotaline, and inducing a heart-kidney yang deficiency state in combination with hydrocortisone intervention from the 15th day; the characteristics of the model are evaluated through multiple indexes such as echocardiography, blood gas analysis, tri-gland axis hormone, energy metabolism, renal functions, biochemical factors, HE staining and ultrastructure observation. Results show that the model has pathological changes of pulmonary arterial hypertension and syndromes such as yang deficiency, water retention, life gate fire decline and the like in traditional Chinese medicine, the construction method is stable and repeatable, and the model is suitable for an experimental platform for traditional Chinese medicine intervention research and combination of traditional Chinese medicine and western medicine.

The invention discloses application of Htr2b and an inhibitor thereof in prevention or treatment of chronic kidney diseases, provides application of Htr2b as a drug target in screening of drugs for prevention or treatment of chronic kidney diseases, and further provides application of the inhibitor of Htr2b in preparation of drugs for prevention or treatment of chronic kidney diseases. It is found that after the Htr2b function of DIO mice is inhibited, kidney injury caused by high fat is obviously relieved, the Htr2b inhibitor can inhibit important inflammatory factors MCP-1, IL-1, IL-6 and TNF-alpha and ectopic lipid deposition of the chronic kidney diseases, renal function markers of creatinine, urea nitrogen and UACR of the DIO mice can be obviously reduced, and the Htr2b inhibitor has the obvious effect of preventing or treating the chronic kidney diseases and has a good application prospect. The compound can be used for preparing medicines for preventing or treating chronic kidney diseases.

The invention provides a compound casein peptide for assisting in improving sleep as well as a preparation method and application thereof, and belongs to the technical field of amino acid polypeptides, the compound casein peptide comprises the following raw materials in parts by weight: 32-36 parts of casein peptide, 28-32 parts of walnut peptide and 34-38 parts of wheat oligopeptide. The invention provides a compound casein peptide for assisting in improving sleep as well as a preparation method and application of the compound casein peptide, so that the effect of assisting in improving sleep of a compound product is good, and the effect of protecting the renal function is achieved.

Described herein are methods for treating subjects with impaired renal (e.g., kidney) function using Compound 1, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of stabilizing renal function in subjects in need thereof using Compound 1, or a pharmaceutically acceptable salt thereof.

The purpose of the present invention is to provide a composition for ameliorating or suppressing the decline of kidney functions and a method for ameliorating or suppressing the decline of kidney functions. The present invention pertains to a composition for ameliorating or suppressing the decline of kidney functions that contains L-ergothioneine or a salt thereof as an active ingredient.

Provided herein are methods of improving kidney function in a subject in need thereof.

Verdazil derivative compounds and compositions thereof, useful as contrast agents for biomedical imaging, are provided. The compounds and compositions of this disclosure can be used, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in subjects, providing a reliable and rapid assessment of renal function.

The invention relates to the technical field of biomedicine, in particular to a preparation method of sequential targeting mesoporous manganese oxide nano-enzyme and application of the sequential targeting mesoporous manganese oxide nano-enzyme in treatment of ischemia reperfusion induced acute kidney injury. Adding a potassium permanganate solution into the silicon dioxide nanoparticle dispersion liquid under ultrasonic waves, and carrying out alkali etching to obtain mesoporous manganese oxide nanoparticles (HMN); and after surface amination modification, connecting with a mixed PEG spacer layer, and reacting with thiolated SS31 and azidoacyl hyaluronic acid to obtain the nano-enzyme. The preparation can effectively penetrate through a damaged glomerulus filtration barrier and is passively enriched in a damaged kidney, damaged renal tubular epithelial cells over-express CD44 receptor mediated hyaluronic acid modified nano-particle endocytosis is enhanced, SS31 modified nano-particles achieve lysosome escape mitochondrial targeting in cells, the level of active oxygen in mitochondria can be reduced, and the activity of the mitochondria can be improved. The mitochondrial function is recovered, the renal function and tissue pathological injury are improved, and accurate anti-oxidation treatment on the acute kidney injury is realized.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.

This document describes a method including reading digital health records each associated with a unique key value representing a patient, each digital health record being structured with a plurality of fields, parsing the plurality of fields to identify the unique key values, and identifying, based on the parsing, a given key value and a digital health record for that given key value. For the identified digital health record, the method includes generating baseline renal function data based on the particular digital health record, comparing the baseline renal function data with current renal function data associated with the given key value, determining that a difference between the baseline renal function data and the current renal function data is greater than a threshold, inputting the current renal function data to a machine learning model, and predicting, by the machine learning model, a propensity of AKI for the given key value.